Literature DB >> 30363830

Highlights of the Stockholm Congress: A Clinician's Perspective.

Oscar S Gershanik1.   

Abstract

Year:  2014        PMID： 30363830      PMCID： PMC6183013          DOI： 10.1002/mdc3.12093

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN： 2330-1619


× No keyword cloud information.
  5 in total

1.  Parkinson's at risk syndrome: can Parkinson's disease be predicted?

Authors:  Matthew B Stern; Andrew Siderowf
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

2.  A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

Authors:  C Warren Olanow; Olivier Rascol; Robert Hauser; Paul D Feigin; Joseph Jankovic; Anthony Lang; William Langston; Eldad Melamed; Werner Poewe; Fabrizio Stocchi; Eduardo Tolosa
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

3.  Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.

Authors:  Carmela Giampà; Daunia Laurenti; Serenella Anzilotti; Giorgio Bernardi; Frank S Menniti; Francesca Romana Fusco
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

4.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.

Authors: 
Journal:  N Engl J Med       Date:  1993-01-21       Impact factor: 91.245

5.  In vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654.

Authors:  Olivier Barret; David Thomae; Adriana Tavares; David Alagille; Caroline Papin; Rikki Waterhouse; Timothy McCarthy; Danna Jennings; Ken Marek; David Russell; John Seibyl; Gilles Tamagnan
Journal:  J Nucl Med       Date:  2014-06-04       Impact factor: 10.057
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.